Wunderlich maintained the shares of UMH in report on Thursday, May 11 with "Buy" rating. (NASDAQ:ACOR) have been given a consensus rating of "Hold" by the fourteen ratings firms that are covering the company, MarketBeat Ratings reports. FMR LLC owned 15.23% of Acorda Therapeutics worth $137,879,000 at the end of the most recent quarter. The forecast of 2 surveyed investment analysts covering the stock advises investors to Buy stake in the company. Municipal Employees Retirement System of MI now owns 10,960 shares of the biopharmaceutical company's stock worth $216,000 after purchasing an additional 410 shares in the last quarter. Parkside Fin Bank holds 0% or 42 shares. Tiaa Cref Invest Mngmt Ltd stated it has 0% in Acorda Therapeutics Inc (NASDAQ:ACOR). Finally, Whittier Trust Co. lifted its stake in Acorda Therapeutics by 2.5% during the 2nd quarter. Corporate insiders own 7.90% of the company's stock. The stock of Acorda Therapeutics Inc (NASDAQ:ACOR) has "Buy" rating given on Monday, March 13 by Janney Capital. (NASDAQ ACOR) opened at 25.85 on Monday. Shares last traded at $25.85 a tad above $23.68, the stock's 50 day moving average and quite a bit above the 200 day moving average of $19.77. Malaga Cove Capital, LLC controls 55,435 shares worth $1,095,000. The value of the total investment in Acorda Therapeutics, Inc. decreased from $303,000 to $268,000 a change of 11.6% since the last quarter. The biopharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.16. The return on equity ratio or ROE stands at -6.4 percent while most common profitability ratio return on investment (ROI) was -3 percent. The firm had revenue of $139.40 million during the quarter, compared to the consensus estimate of $139.81 million. During the same quarter in the prior year, the company posted $0.07 earnings per share. For the past 5 years, the company's revenue has grown -11.7%, while the company's earnings per share has grown 85.6%. On average, analysts anticipate that Acorda Therapeutics, Inc. will post $1.71 earnings per share for the current fiscal year.
Several other large investors also recently added to or reduced their stakes in ACOR. Goldman Sachs invested in 0% or 534,956 shares. Acorda Therapeutics had 25 analyst reports since August 25, 2015 according to SRatingsIntel. Scopia Capital Management Lp acquired 1.66M shares as Acorda Therapeutics Inc (ACOR)'s stock declined 39.72%. 0 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. They set a "hold" rating and a $22.00 price objective on the stock. $338,998 worth of stock was bought by COHEN RON on Friday, June 16. Following the completion of the sale, the director now directly owns 10,000 shares of the company's stock, valued at approximately $215,700. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Barry E. Greene sold 10,000 shares of the firm's stock in a transaction on Tuesday, August 1st. The stock was purchased at an average cost of $19.23 per share, for a total transaction of $14,734,045.23. The disclosure for this sale can be found here. Insiders sold 20,250 shares of company stock worth $438,650 over the last ninety days.
TRADEMARK VIOLATION NOTICE: "Acorda Therapeutics, Inc. (ACOR) at Sell" with publication date: October 06, 2017. Cornerstone Capital Management Hldgs Limited Company reported 0.01% in Acorda Therapeutics Inc (NASDAQ:ACOR). The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration -approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).
Want to see what other hedge funds are holding ACOR?